# Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Canonical URL: https://biopharmsignal.com/news/NKTR/nektar-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4
Ticker: NKTR
Company: Nektar Therapeutics
Source: Nektar Therapeutics
Published: 2026-05-01 20:39 EST
Original Source URL: https://ir.nektar.com
## Summary

SAN FRANCISCO, May 1, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on April 20, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified stock options to purchase an aggregate of 28,450 shares of its common stock and

## Article Body
SAN FRANCISCO, May 1, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on April 20, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified stock options to purchase an aggregate of 28,450 shares of its common stock and
## Recent Company News
- 2026-05-27 22:15 EST — [Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York](https://biopharmsignal.com/news/NKTR/nektar-therapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conference-in-new-york) — Source: Nektar Therapeutics
- 2026-05-07 20:15 EST — [Nektar Therapeutics Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/NKTR/nektar-therapeutics-reports-first-quarter-2026-financial-results) — Source: Nektar Therapeutics
- 2026-05-01 20:39 EST — [Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/NKTR/nektar-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4) — Source: Nektar Therapeutics
- 2026-04-28 22:00 EST — [Nektar to Announce Financial Results for the First Quarter on Thursday, May 7, 2026, After Close of U.S.-Based Financial Markets](https://biopharmsignal.com/news/NKTR/nektar-to-announce-financial-results-for-the-first-quarter-on-thursday-may-7-2026-after-close-of-u-s-based-financial-markets) — Source: Nektar Therapeutics
- 2026-04-23 20:15 EST — [Nektar Therapeutics Announces Closing of $373.8 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares](https://biopharmsignal.com/news/NKTR/nektar-therapeutics-announces-closing-of-373-8-million-public-offering-including-full-exercise-of-underwriters-option-to-purchase-additional-shares) — Source: Nektar Therapeutics
## Related News
- 2026-07-21 20:15 EST — BFRG — [BullFrog AI to Participate in Water Tower Research Fireside Chat on Thursday, July 23, 2026](https://biopharmsignal.com/news/BFRG/bullfrog-ai-to-participate-in-water-tower-research-fireside-chat-on-thursday-jul-78357ce8)
- 2026-07-21 20:05 EST — CLPT — [ClearPoint Neuro to Announce Second Quarter 2026 Results August 3, 2026](https://biopharmsignal.com/news/CLPT/clearpoint-neuro-to-announce-second-quarter-2026-results-august-3-2026-6e4f3c05)
- 2026-07-21 20:05 EST — TCMD — [Tactile Medical to Release Second Quarter of Fiscal Year 2026 Financial Results on August 10, 2026](https://biopharmsignal.com/news/TCMD/tactile-medical-to-release-second-quarter-of-fiscal-year-2026-financial-results--798d4004)
- 2026-07-21 20:05 EST — PIII — [P3 Health Partners Schedules Second Quarter 2026 Earnings Release and Conference Call](https://biopharmsignal.com/news/PIII/p3-health-partners-schedules-second-quarter-2026-earnings-release-and-conference-6c9bd8a7)
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)